Angiotech Pharmaceuticals
From Wikipedia, the free encyclopedia
| Type | Public (OTCBB: ANPIQ) |
|---|---|
| Industry | Pharmaceutical |
| Headquarters | Vancouver, British Columbia, Canada |
| Key people | K. Thomas Bailey |
| Employees | 1450[1] |
| Website | www.angiotech.com |
Angiotech (OTCBB: ANPIQ) is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.
In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins. [2]
[edit] References
- ^ "Company Profile for Angiotech Pharmaceuticals Inc (CA;ANP)". http://zenobank.com/index.php?symbol=CA;ANP&page=quotesearch. Retrieved 2008-10-10.
- ^ Angiotech acquired Haemacure Retrieved on 7th April 2010 from Medical Devices Business Review
[edit] External links
- Official site
- Company Profile at Medical Devices Business Review
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 |
This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |
